Similarities and differences in the conformational stability and reversibility of ORF8, an accessory protein of SARS-CoV-2, and its L84S variant.


Journal

Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516

Informations de publication

Date de publication:
23 07 2021
Historique:
received: 11 05 2021
accepted: 19 05 2021
pubmed: 2 6 2021
medline: 25 6 2021
entrez: 1 6 2021
Statut: ppublish

Résumé

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has the characteristic accessory protein ORF8. Although clinical reports indicate that ORF8 variant strains (Δ382 and L84S variants) are less likely to cause severe illness, functional differences between wild-type and variant ORF8 are unknown. Furthermore, the physicochemical properties of the ORF8 protein have not been analyzed. In this study, the physicochemical properties of the wild-type ORF8 and its L84S variant were analyzed and compared. Using the tobacco BY-2 cell production system, which has been successfully used to produce the wild-type ORF8 protein with a single conformation, was used to successfully produce the ORF8 L84S variant protein at the same level as wild-type ORF8. The produced proteins were purified, and their temperature and pH dependencies were examined using nuclear magnetic resonance spectra. Our data suggested that the wild-type and L84S variant ORF8 structures are highly stable over a wide temperature range. Both proteins displayed an aggregated conformation at higher temperature that reverted when the temperature was decreased to room temperature. Moreover, ORF8 precipitated at acidic pH and this precipitation was reversed when the solution pH was shifted to neutral. Interestingly, the L84S variant exhibited greater solubility than wild-type ORF8 under acidic conditions. Thus, the finding indicated that conformational stability and reversibility of ORF8 are key properties related to function in oppressive environments.

Identifiants

pubmed: 34062392
pii: S0006-291X(21)00857-3
doi: 10.1016/j.bbrc.2021.05.074
pmc: PMC8149210
pii:
doi:

Substances chimiques

ORF8 protein, SARS-CoV-2 0
Recombinant Proteins 0
Viral Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

92-97

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Nat Immunol. 2020 Oct;21(10):1293-1301
pubmed: 32807944
J Biomol NMR. 2008 Dec;42(4):271-7
pubmed: 18937031
Arch Virol. 2006 Jun;151(6):1075-84
pubmed: 16421635
Science. 2014 Apr 11;344(6180):168-72
pubmed: 24723605
iScience. 2021 Apr 23;24(4):102293
pubmed: 33723527
Int J Antimicrob Agents. 2021 Feb;57(2):106272
pubmed: 33347989
Lancet. 2020 Aug 29;396(10251):603-611
pubmed: 32822564
Nat Rev Mol Cell Biol. 2010 Jan;11(1):50-61
pubmed: 19997129
Nat Protoc. 2015 Jun;10(6):845-58
pubmed: 25950237
Plant Cell Rep. 2021 Mar;40(3):433-436
pubmed: 33399879
EMBO J. 2003 Jan 15;22(2):344-53
pubmed: 12514140
Nat Commun. 2011 Oct 25;2:512
pubmed: 22027592
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):395-403
pubmed: 32334395
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
mBio. 2020 Oct 20;11(5):
pubmed: 33082264
mBio. 2020 May 29;11(3):
pubmed: 32471829
Proc Natl Acad Sci U S A. 2021 Jan 12;118(2):
pubmed: 33361333
Lancet Diabetes Endocrinol. 2021 Feb;9(2):82-93
pubmed: 33357491
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508

Auteurs

Shinya Ohki (S)

Center for Nano Materials and Technology (CNMT), Japan Advanced Institute of Science and Technology (JAIST), 1-1 Asahidai, Nomi, Ishikawa, 923-1292, Japan. Electronic address: shinya-o@jaist.ac.jp.

Tomohiro Imamura (T)

Department of Bioproduction Science, Ishikawa Prefectural University, 308-1 Suematsu, Nonoichi, Ishikawa, 921-8836, Japan.

Yasuki Higashimura (Y)

Department of Food Science, Ishikawa Prefectural University, 308-1 Suematsu, Nonoichi, Ishikawa, 921-8836, Japan.

Kenji Matsumoto (K)

Department of Food Science, Ishikawa Prefectural University, 308-1 Suematsu, Nonoichi, Ishikawa, 921-8836, Japan.

Masashi Mori (M)

Research Institute for Bioresources and Biotechnology, Ishikawa Prefectural University, 308-1 Suematsu, Nonoichi, Ishikawa, 921-8836, Japan. Electronic address: mori@ishikawa-pu.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH